Osteo-cartilaginous pain syndromes at the chest wall: results of costal cartilage excision.

Background: Various pathologies of the lower ribs may lead to potentially severe pain in a heterogenous group of patients. Costal cartilage excision (CCE) has been shown to result in durable pain relief in some patients. Even though literature is scarce, we reviewed our experience with surgically treated osteo-cartilaginous pain syndromes (OCPSs) of the chest wall. Methods: We performed a retrospective case series from two institutions including patients operated for OCPS from 2014 to 2022. Results: Our case series consists of 11 patients (72.7% female) with OCPS that were treated by CCE. The median age was 43.5±17.1 years. Body mass index (BMI) was 23.6±3.4 kg/m2 (range, 18.5-29.6). The interval between first symptoms and diagnosis was 2.6 years (range, 3-127). In 5 patients, symptoms started after preceding chest wall trauma. All but one case were unilateral with no significant predominance regarding the side (6 left/4 right/1 bilateral). Postoperative length of hospital stay was 2.3±0.6 days. There was no patient morbidity or mortality. At follow-up, OCPS related pain had ceased in 7 of 9 patients (78%). Two patients stated to have significantly less pain and two patients didn't have a follow-up. Conclusions: Our analysis indicates that CCE in OCPS is safe and has good long-term results.

[Risky confirmation of a diagnosis: case series of three female patients with mediastinal mass syndrome]. / Riskante Diagnosesicherung: Fallserie über drei Patientinnen mit Mediastinal-mass-Syndrom.

Mediastinal mass syndrome (MMS) is a life-threatening complication of anesthesia for which prevention and treatment are a complication-prone interdisciplinary task. Clinical symptoms vary from asymptomatic patients up to life-threatening cardiorespiratory impairments, depending on the extent and size of a mediastinal tumor as well as the involvement of corresponding anatomical structures. Especially in the context of sedation or general anesthesia, there is a considerable risk of acute cardiopulmonary or respiratory decompensation related to tumor-induced compression of central blood vessels or even the large airways, which may result in severe complications, including death. In this case series three female patients are presented, who were each referred to this hospital with a mediastinal tumor for interventional or surgical confirmation of the diagnosis. Based on the case histories, characteristic complications are demonstrated and strategies to avoid possible adverse events of MMS are discussed. The specific anesthesiological requirements for MMS, the safety aspects of the choice of surgical and anesthesia procedures, circulatory and airway management for the required single-lung ventilation, and various aspects of the selection of the anesthetic agents are discussed in this case series.

[Robotic-assisted Thoracic Surgery]. / Roboterassistierte Thoraxchirurgie.

In the last decade robotic-assisted thoracoscopic surgery (RATS) emerged as a new minimally invasive surgical modality to operate pulmonary, mediastinal and esophageal diseases. Superior to video-assisted thoracoscopic surgery (VATS), RATS affords accurate surgical manipulation in spatially confined anatomical regions. Numerous surgical case studies demonstrated technical reliability and oncological equivalence of RATS compared to open surgery and VATS. Consequently, the number of RATS operations for oncological and non-oncological resections is rising rapidly. The lacking evidence of therapy improvement in the context of significantly increased treatment costs slows the development. Currently, various new companies introduce new robotic surgical platforms into the market and it is expected that market competition will change the costs of these modern therapies. This article summarizes the technical features of RATS and its anesthesiologic implications for patient management.

Gilbert syndrome redefined: a complex genetic haplotype influences the regulation of glucuronidation.

UNLABELLED: Gilbert syndrome (GS) is characterized by intermittent unconjugated hyperbilirubinemia without structural liver damage, affecting about 10% of the white population. In GS the UGT1A1*28 variant reduces bilirubin conjugation by 70% and is associated with irinotecan and protease inhibitor side effects. The aim of this study was to characterize potential in vivo consequences of UGT1A gene variability in GS. Three hundred GS patients (UGT1A1*28 homozygous) and 249 healthy blood donors (HBD) were genotyped for UGT1A (UGT1A1*28, UGT1A3-66 T>C, UGT1A6*3a, UGT1A7*3) and transporter single nucleotide polymorphisms (SNPs) (SCLO1B1 p.V174A, SCLO1B1 p.N130D, ABCC2 p.I1324I, ABCC2-24 UTR) using TaqMan-5'-nuclease-assays. A humanized transgenic UGT1A-SNP and corresponding wildtype mouse model were established carrying the GS-associated UGT1A variant haplotype. UGT1A transcript and protein expression, and transcriptional activation were studied in vivo. Homozygous UGT1A1*28 GS individuals were simultaneously homozygous for UGT1A3-66 T>C (91%), UGT1A6*2a (77%), and UGT1A7*3 (77%). Seventy-six percent of GS and only 9% of HBD were homozygous for the variant haplotype spanning four UGT1A genes. SCLO1B1 and ABCC2 SNPs showed no differences. In transgenic humanized UGT1A SNP and wildtype mice this UGT1A haplotype led to lower UGT1A messenger RNA (mRNA) expression and UGT1A protein synthesis. UGT1A transcriptional activation by dioxin, phenobarbital, and endotoxin was significantly reduced in SNP mice. CONCLUSION: Our data redefine the genetic basis behind GS. In vivo data studying the genotype present in 76% of GS individuals suggest that transcription and transcriptional activation of glucuronidation genes responsible for conjugation and detoxification is directly affected, leading to lower responsiveness. This study suggests that GS should be considered a potential risk factor for drug toxicity.